NASDAQ:CNTX Context Therapeutics (CNTX) Stock Price, News & Analysis $0.88 +0.00 (+0.11%) As of 03:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Context Therapeutics Stock (NASDAQ:CNTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Context Therapeutics alerts:Sign Up Key Stats Today's Range$0.88▼$0.9150-Day Range$0.56▼$0.9152-Week Range$0.49▼$2.62Volume66,001 shsAverage Volume201,983 shsMarket Capitalization$79.03 millionP/E RatioN/ADividend YieldN/APrice Target$5.25Consensus RatingBuy Company Overview Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania. Read More Context Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks75th Percentile Overall ScoreCNTX MarketRank™: Context Therapeutics scored higher than 75% of companies evaluated by MarketBeat, and ranked 277th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingContext Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageContext Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Context Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Context Therapeutics are expected to grow in the coming year, from ($0.51) to ($0.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Context Therapeutics is -2.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Context Therapeutics is -2.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioContext Therapeutics has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Context Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.09% of the float of Context Therapeutics has been sold short.Short Interest Ratio / Days to CoverContext Therapeutics has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Context Therapeutics has recently decreased by 24.38%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldContext Therapeutics does not currently pay a dividend.Dividend GrowthContext Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.09% of the float of Context Therapeutics has been sold short.Short Interest Ratio / Days to CoverContext Therapeutics has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Context Therapeutics has recently decreased by 24.38%, indicating that investor sentiment is improving significantly. News and Social Media3.8 / 5News Sentiment0.84 News SentimentContext Therapeutics has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Context Therapeutics this week, compared to 2 articles on an average week.Search Interest5 people have searched for CNTX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat Follows3 people have added Context Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Context Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $107,206.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.80% of the stock of Context Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 14.03% of the stock of Context Therapeutics is held by institutions.Read more about Context Therapeutics' insider trading history. Receive CNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CNTX Stock News HeadlinesContext Therapeutics Reports Q2 2025 Financial Results4 hours ago | msn.comContext Therapeutics Inc. (NASDAQ:CNTX) Receives $5.25 Average Price Target from AnalystsAugust 20 at 2:49 AM | americanbankingnews.comOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol quietly prints $1 million in fees every single day.August 22 at 2:00 AM | Crypto 101 Media (Ad)Context Therapeutics Highlights Pipeline Progress, Reports $8.8M Loss in Q2August 8, 2025 | msn.comContext Therapeutics Reports Second Quarter 2025 Operating and Financial ResultsAugust 6, 2025 | globenewswire.comContext Therapeutics Presents CTIM-76 Phase 1 Trial in Progress at ASCO 2025July 25, 2025 | msn.comContext Therapeutics Approves Reverse Stock Split AmendmentJune 12, 2025 | tipranks.comCo-Founder of Context Therapeutics Martin Lehr Buys 10% More SharesJune 11, 2025 | finance.yahoo.comSee More Headlines CNTX Stock Analysis - Frequently Asked Questions How have CNTX shares performed this year? Context Therapeutics' stock was trading at $1.05 at the beginning of 2025. Since then, CNTX shares have decreased by 16.1% and is now trading at $0.8810. How were Context Therapeutics' earnings last quarter? Context Therapeutics Inc. (NASDAQ:CNTX) posted its quarterly earnings data on Wednesday, August, 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by $0.03. When did Context Therapeutics IPO? Context Therapeutics (CNTX) raised $25 million in an initial public offering on Wednesday, October 20th 2021. The company issued 5,000,000 shares at a price of $5.00 per share. Who are Context Therapeutics' major shareholders? Top institutional shareholders of Context Therapeutics include Affinity Asset Advisors LLC (0.58%), Walleye Capital LLC (0.15%) and Qube Research & Technologies Ltd (0.12%). Insiders that own company stock include Martin A Lehr, Jennifer Lynn Minai-Azary and Alex C Levit. View institutional ownership trends. How do I buy shares of Context Therapeutics? Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Context Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Context Therapeutics investors own include NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Arista Networks (ANET), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Celestica (CLS). Company Calendar Last Earnings8/06/2025Today8/22/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNTX CIK1842952 Webwww.contexttherapeutics.com Phone267-225-7416FaxN/AEmployees7Year FoundedN/APrice Target and Rating Average Price Target for Context Therapeutics$5.25 High Price Target$9.00 Low Price Target$4.00 Potential Upside/Downside+495.9%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.73 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.80% Return on Assets-37.53% Debt Debt-to-Equity RatioN/A Current Ratio19.09 Quick Ratio19.09 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.92 per share Price / Book0.96Miscellaneous Outstanding Shares89,700,000Free Float87,192,000Market Cap$79.03 million OptionableNot Optionable Beta1.89 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CNTX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.